Cancidas (caspofungin acetate) for Injection, for Intravenous Use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) April 2016 ADVERSE REACTIONS Postmarketing Experience … toxic epidermal necrolysis…Stevens-Johnson syndrome… ...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts